Signaturefd LLC increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 1.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,836 shares of the biopharmaceutical company’s stock after buying an additional 47 shares during the period. Signaturefd LLC’s holdings in Celgene Corp. were worth $378,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of CELG. Carmignac Gestion increased its position in shares of Celgene Corp. by 28.1% in the second quarter. Carmignac Gestion now owns 9,708,359 shares of the biopharmaceutical company’s stock valued at $957,535,000 after buying an additional 2,127,659 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Celgene Corp. by 29.3% in the first quarter. Wellington Management Group LLP now owns 9,105,975 shares of the biopharmaceutical company’s stock valued at $911,417,000 after buying an additional 2,062,585 shares in the last quarter. Orbis Allan Gray Ltd bought a new position in shares of Celgene Corp. during the first quarter valued at about $119,631,000. Bank of Montreal Can bought a new position in shares of Celgene Corp. during the second quarter valued at about $117,274,000. Finally, Bristol John W & Co. Inc. NY bought a new position in shares of Celgene Corp. during the second quarter valued at about $52,246,000. Institutional investors own 77.75% of the company’s stock.
Celgene Corp. (NASDAQ:CELG) traded down 2.12% on Friday, hitting $98.50. 4,317,515 shares of the stock traded hands. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $128.39. The stock has a 50-day moving average price of $105.76 and a 200 day moving average price of $105.48. The stock has a market cap of $76.35 billion, a P/E ratio of 41.63 and a beta of 1.49.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.05. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The business’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS. On average, equities analysts expect that Celgene Corp. will post $5.71 EPS for the current fiscal year.
Several research analysts recently issued reports on the company. Argus restated a “buy” rating and set a $155.00 price objective on shares of Celgene Corp. in a research report on Wednesday, September 7th. Cowen and Company reaffirmed a “buy” rating and issued a $150.00 target price on shares of Celgene Corp. in a research note on Thursday, July 28th. Leerink Swann reaffirmed a “market perform” rating and issued a $135.00 target price on shares of Celgene Corp. in a research note on Monday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $138.00 target price on shares of Celgene Corp. in a research note on Tuesday, August 2nd. Finally, Vetr cut shares of Celgene Corp. from a “hold” rating to a “sell” rating and set a $104.37 target price for the company. in a research note on Monday, July 25th. Three analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $136.46.
In other news, insider Robert J. Hugin sold 100,000 shares of the firm’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the completion of the transaction, the insider now directly owns 1,022,201 shares of the company’s stock, valued at approximately $112,442,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael A. Friedman sold 56,116 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $103.66, for a total transaction of $5,816,984.56. Following the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at $5,183,000. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.
About Celgene Corp.
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).
Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.